270 related articles for article (PubMed ID: 36736928)
61. Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates.
Montero MM; Domene-Ochoa S; López-Causapé C; López-Montesinos I; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Ferrer Alapont L; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2022 Jun; 10(3):e0089222. PubMed ID: 35695526
[TBL] [Abstract][Full Text] [Related]
62. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
[TBL] [Abstract][Full Text] [Related]
63. Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against
Shortridge D; Pfaller MA; Arends SJR; Raddatz J; DePestel DD; Flamm RK
Open Forum Infect Dis; 2019 Jun; 6(6):ofz240. PubMed ID: 31263733
[TBL] [Abstract][Full Text] [Related]
64. Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021).
Walkty A; Karlowsky JA; Lagacé-Wiens PRS; Baxter MR; Adam HJ; Bay DC; Zhanel GG
Diagn Microbiol Infect Dis; 2024 Feb; 108(2):116130. PubMed ID: 38006710
[TBL] [Abstract][Full Text] [Related]
65. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
66. Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.
O'Neall D; Juhász E; Tóth Á; Urbán E; Szabó J; Melegh S; Katona K; Kristóf K
Acta Microbiol Immunol Hung; 2020 Mar; 67(1):61-65. PubMed ID: 32208923
[TBL] [Abstract][Full Text] [Related]
67. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
68. Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
Haines RR; Putsathit P; Hammer KA; Tai AS
Sci Rep; 2022 Oct; 12(1):16814. PubMed ID: 36207358
[TBL] [Abstract][Full Text] [Related]
69. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program.
Shortridge D; Pfaller MA; Castanheira M; Flamm RK
Diagn Microbiol Infect Dis; 2018 Oct; 92(2):158-163. PubMed ID: 29891184
[TBL] [Abstract][Full Text] [Related]
70. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
71. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
72. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
[TBL] [Abstract][Full Text] [Related]
73. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis.
Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE
J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421
[TBL] [Abstract][Full Text] [Related]
74.
Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
[TBL] [Abstract][Full Text] [Related]
75. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.
Monogue ML; Nicolau DP
J Antimicrob Chemother; 2018 Apr; 73(4):942-952. PubMed ID: 29272436
[TBL] [Abstract][Full Text] [Related]
76. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
[TBL] [Abstract][Full Text] [Related]
77. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
Karlowsky JA; Lob SH; Young K; Motyl MR; Sahm DF
BMC Microbiol; 2021 Mar; 21(1):74. PubMed ID: 33676406
[TBL] [Abstract][Full Text] [Related]
78. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
79. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
80. Ceftolozane/Tazobactam Activity Against Drug-Resistant
Pfaller M; Shortridge D; Chen WT; Sader H; Castanheira M
Infect Drug Resist; 2022; 15():6739-6753. PubMed ID: 36444213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]